| Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study G Cavalli, G De Luca, C Campochiaro, E Della-Torre, M Ripa, D Canetti, ... The Lancet Rheumatology 2 (6), e325-e331, 2020 | 1052 | 2020 |
| GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study G De Luca, G Cavalli, C Campochiaro, E Della-Torre, P Angelillo, ... The Lancet Rheumatology 2 (8), e465-e473, 2020 | 226 | 2020 |
| Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study G Cavalli, A Larcher, A Tomelleri, C Campochiaro, E Della-Torre, ... The Lancet Rheumatology 3 (4), e253-e261, 2021 | 168 | 2021 |
| Low prevalence of arrhythmias in clinically stable COVID‐19 patients S Sala, G Peretto, G De Luca, N Farina, C Campochiaro, M Tresoldi, ... Pacing and Clinical Electrophysiology 43 (8), 891-893, 2020 | 60 | 2020 |
| Obesity and its role in the management of rheumatoid and psoriatic arthritis L Moroni, N Farina, L Dagna Clinical rheumatology 39 (4), 1039-1047, 2020 | 57 | 2020 |
| Tocilizumab for the treatment of immune-related adverse events: a systematic literature review and a multicentre case series C Campochiaro, N Farina, A Tomelleri, R Ferrara, C Lazzari, A Bulotta, ... European Journal of Internal Medicine, 2021 | 49 | 2021 |
| Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. Lancet … G Cavalli, G De Luca, C Campochiaro, E Della-Torre, M Ripa, D Canetti, ... DOI: https://doi. org/10.1016/S2665-9913 (20), 30127-2, 2021 | 49 | 2021 |
| Repurposing of biologic and targeted synthetic anti-rheumatic drugs in COVID-19 and hyper-inflammation: a comprehensive review of available and emerging evidence at the peak of … G Cavalli, N Farina, C Campochiaro, G De Luca, E Della-Torre, ... Frontiers in pharmacology 11, 598308, 2020 | 41 | 2020 |
| Biobanking for COVID-19 research P Medica Panminerva Medica, 2020 | 39 | 2020 |
| Presenting features and outcomes of cranial-limited and large-vessel giant cell arteritis: a retrospective cohort study A Tomelleri, C Campochiaro, S Sartorelli, N Farina, E Baldissera, ... Scandinavian journal of rheumatology 51 (1), 59-66, 2022 | 23 | 2022 |
| COVID-19: pharmacology and kinetics of viral clearance N Farina, GA Ramirez, R De Lorenzo, L Di Filippo, C Conte, F Ciceri, ... Pharmacological Research 161, 105114, 2020 | 23 | 2020 |
| Efficacy and improved tolerability of combination therapy with interleukin-1 blockade and MAPK pathway inhibitors for the treatment of Erdheim-Chester disease C Campochiaro, G Cavalli, N Farina, A Tomelleri, G De Luca, L Dagna Annals of the Rheumatic Diseases 81 (1), e11-e11, 2022 | 21 | 2022 |
| Drug retention rates of biological agents in adult onset Still's disease C Campochiaro, N Farina, A Tomelleri, G De Luca, E Baldissera, ... Seminars in Arthritis and Rheumatism 51 (1), 1-6, 2021 | 18 | 2021 |
| Current treatment options and safety considerations when treating adult-onset Still’s disease G Cavalli, N Farina, C Campochiaro, E Baldissera, L Dagna Expert Opinion on Drug Safety 19 (12), 1549-1558, 2020 | 18 | 2020 |
| Giant cell arteritis: Update on clinical manifestations, diagnosis, and management N Farina, A Tomelleri, C Campochiaro, L Dagna European Journal of Internal Medicine 107, 17-26, 2023 | 17 | 2023 |
| Impact of the COVID-19 pandemic in patients with systemic lupus erythematosus throughout one year GA Ramirez, LM Argolini, C Bellocchi, L Moroni, E Della-Torre, N Farina, ... Clinical Immunology 231, 108845, 2021 | 15 | 2021 |
| Age at diagnosis influences the clinical phenotype, treatment strategies and outcomes in patients with giant cell arteritis: results from the observational GCAGE study on a … S Monti, A Milanesi, C Klersy, A Tomelleri, L Dagna, C Campochiaro, ... Annals of the Rheumatic Diseases 82 (8), 1098-1106, 2023 | 12 | 2023 |
| Antiphospholipid antibody positivity in early systemic lupus erythematosus is associated with subsequent vascular events N Farina, R Abdulsalam, T McDonnell, C Pericleous, A D’Souza, ... Rheumatology 62 (6), 2252-2256, 2023 | 11 | 2023 |
| Long-term clinical outcome in systemic lupus erythematosus patients followed for more than 20 years: the Milan systemic lupus erythematosus consortium (SMiLE) cohort M Gerosa, L Beretta, GA Ramirez, E Bozzolo, M Cornalba, C Bellocchi, ... Journal of Clinical Medicine 11 (13), 3587, 2022 | 10 | 2022 |
| Effectiveness of a two-year tapered course of tocilizumab in patients with giant cell arteritis: a single-centre prospective study A Tomelleri, C Campochiaro, N Farina, L Mariotti, E Baldissera, ... Seminars in arthritis and rheumatism 59, 152174, 2023 | 9 | 2023 |
